New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia.

ABSTRACT: Ventilator-associated pneumonia (VAP) remains an important clinical problem globally, being associated with significant morbidity and mortality. As management of VAP requires adequate and timely antibiotic administration, global emergence of antimicrobial resistance poses serious challenges over our ability to maintain this axiom. Development of antimicrobials against MDR Gram-negative pathogens has therefore emerged as a priority and some new antibiotics have been marketed or approach late stage of development. The aim of this review is to analyse new therapeutic options from the point view of potential treatment of VAP. Among recently developed antimicrobials presented herein, it is obvious that we will have promising therapeutic options against VAP caused by Enterobacteriaceae ex

SUBMITTER: Poulakou G 

PROVIDER: S-EPMC6275416 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature